Global Health Bulletin: Major Updates on Disease Outbreaks and Medical Innovations

Recent health news includes an outbreak of bluetongue disease in Norway, IPO targets for Zenas BioPharma and Bicara Therapeutics, advancements in mouse skin research, and enhanced mpox testing in the US. Further highlights cover new asthma drug findings, Ozempic counterfeit issues, and Congo's acquisition of critical mpox vaccines.

A recent summary of health news has brought significant insights into global medical developments and disease outbreaks.

Norway reported an outbreak of bluetongue disease in sheep, according to the World Organisation for Animal Health (WOAH). This disease can be lethal for domestic ruminants. Meanwhile, Zenas BioPharma, backed by Bristol-Myers Squibb, aims for a substantial $689.7 million valuation in its US IPO.

Bicara Therapeutics is also seeking a high valuation of up to $828 million in its IPO, highlighting a robust market for new listings. In scientific advancements, a new dye can make mouse skin invisible, aiding researchers. Additionally, the US has enhanced mpox testing and vaccine access amid concerns of a new strain. GSK's asthma drug Nucala has shown promising results in treating chronic obstructive pulmonary disease.

In other news, a fake Ozempic batch incident raises alarm over counterfeit drugs, and China has banned poultry imports from Poland following an avian flu outbreak. Congo received its first mpox vaccine doses to combat a severe outbreak.

(With inputs from agencies.)